Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.314
+0.017 (5.76%)
Nov 4, 2024, 3:59 PM EST - Market closed
Oragenics Revenue
Oragenics had revenue of $7.47K in the twelve months ending June 30, 2024, down -93.58% year-over-year. In the year 2023, Oragenics had annual revenue of $37.65K, down -71.37%.
Revenue (ttm)
$7.47K
Revenue Growth
-93.58%
P/S Ratio
129.03
Revenue / Employee
$1,493
Employees
5
Market Cap
3.53M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOGEN News
- 17 days ago - Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewsWire
- 26 days ago - Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewsWire
- 27 days ago - Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 2 months ago - Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 2 months ago - Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range - GlobeNewsWire